Abstract: The present invention is directed to methods for inhibiting growth of bacteria and to nanometer scale surfaces having antibacterial properties.
Abstract: In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.
Abstract: The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging:
Type:
Grant
Filed:
August 23, 2017
Date of Patent:
December 27, 2022
Assignee:
Simon Fraser University
Inventors:
Paul Schaffer, Hua Yang, Robert Britton, Matthew Nodwell, Zheliang Yuan
Abstract: Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.
Type:
Grant
Filed:
April 13, 2020
Date of Patent:
December 20, 2022
Assignee:
Surmodics, Inc.
Inventors:
Joram Slager, Toni M. Heyer, David E. Babcock
Abstract: There is provided a method of preparing silica nanocapsules, the method comprising mixing a surfactant with water at a temperature that is above the gel-to-liquid transition temperature of the surfactant to form a mixture, passing the mixture one or more times through at least one pore to obtain a dispersion of vesicles, and adding a silica precursor to the dispersion of vesicles to form silica nanocapsules. Also provided is a silica nanocapsule formed from a vesicle template, and a method of delivering one or more types of molecules to a subject. In a specific embodiment, hollow silica nanocapsules having substantially lens-shaped are synthesized by employing dimethyldioctadecylammonium bromide (DODAB) or dioctadecyldimethyl ammonium chloride (DODAC) as the vesicle template and tetraethyl orthosilicate (TEOS) as the silica precursor.
Type:
Grant
Filed:
March 28, 2018
Date of Patent:
December 20, 2022
Assignee:
Agency for Science, Technology and Research
Inventors:
Eun Ju Park, Alexander M. Van Herk, Praveen Thoniyot
Abstract: The present disclosure relates to compositions and methods of carbonic anhydrase IX inhibitors. The present disclosure also relates to targeting conjugates of carbonic anhydrase IX inhibitors. The present disclosure also relates to the use of targeting conjugates of carbonic anhydrase IX inhibitors in methods of treating disease and for imaging of disease.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
December 13, 2022
Assignee:
Purdue Research Foundation
Inventors:
Philip S. Low, Isaac J. Marks, Spencer Gardeen, Sumith A. Kularatne
Abstract: Disclosed are methods useful for the topical therapeutic treatment of cervical intraepithelial neoplasia (CIN) and/or cervical cancer using compositions containing nanoparticles of paclitaxel or other taxanes.
Abstract: The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in prevention or treatment of a neurological disease or at least one symptom thereof in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above 200, and an insulator material with a dielectric constant ?ijk equal to or below 100.
Abstract: The invention generally relates to compositions of hypochlorous acid (HOCl) and methods of manufacture thereof. In certain aspects, the invention provides air-free compositions of HOCl. In other aspects, the invention provides methods of making HOCl that involve mixing together in water in an air-free environment, a compound that generates a proton (H+) in water and a compound that generates a hypochlorite anion (OCl?) in water to thereby produce air-free hypochlorous acid.
Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating biofilms in or on tissue, including biofilms related to wounds or other skin trauma. The compositions are useful for treating a variety of types of tissue, both on the surface on beneath the surface of tissue. Compositions are provided for treating biofilms without inducing antimicrobial resistance.
Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.
Abstract: The present invention relates to the medical field, in particular to the enhancement of brain performances and for the treatment of pathological stress. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use in enhancing brain performances or in prevention or treatment of pathological stress in a subject without exposure of the nanoparticle or nanoparticles' aggregate to an electric field, and preferably without exposure thereof to any other external activation source, wherein the nanoparticle's or nanoparticles' aggregate's material is selected from a conductor material, a semiconductor material, an insulator material with a dielectric constant ?ijk equal to or above (200), and an insulator material with a dielectric constant ?ijk equal to or below (100).
Abstract: The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to 99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with 99mTc-pertechnetate solution gives stabilized 99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.
Type:
Grant
Filed:
October 7, 2019
Date of Patent:
October 18, 2022
Inventors:
Harmik Sohi, Rahul Hasija, Basant Malik, Kamal S. Mehta, Dinesh Kumar
Abstract: The present invention provides an improved process for preparing microparticles containing glatiramer acetate having low levels of residual organic solvent(s), in particular dichloromethane. The microparticles are incorporated into long acting parenteral pharmaceutical compositions in depot form that are suitable for subcutaneous or intramuscular implantation or injection, and that may be used to treat multiple sclerosis.
Abstract: The present invention is inserted in the fields of nanotechnology, pharmacy and genetics and refers to specific sequences of interference RNA (siRNA), capable of silencing the gene responsible for the expression of an adhesion protein, which produces overexpressed extracellular adenosine in tumors, the enzyme ecto-5?-nucleotidase/CD73 (CD73). The specific siRNA sequences for CD73 are proposed in a nanometer scale composition in the form of liposomes or nanoemulsions in order to promote a site-directed release complex capable of being incorporated into several types of formulation, such as intratumor, intravenous injection or administration nasal. The siRNA sequences to silence CD73 can also be applied in the manufacture of kits and/or in silencing tests of CD73 for scientific research using liposomes, nanoemulsions or other transfection reagents.
Type:
Grant
Filed:
January 7, 2019
Date of Patent:
October 4, 2022
Inventors:
Elizandra Braganhol, Ana Maria Oliveira Battastini, Helder Teixeira, Marco Antônio Stefani, Fernanda Bruxel, Roselia Maria Spanevello, Fernanda Cardoso Teixeira, Juliana Hofstatter Azambuja
Abstract: Disinfecting compositions containing hypochlorous acid and acetic acid are useful for treating transient biofilms in or on tissue without harming the natural flora of the tissue. The compositions are useful for treating a variety of types of tissue. Compositions are useful for treating and preventing orally-associated biofilm. Compositions may be provided in mouthwash form, spray form, gel form, cream form, dentifrice form, and may include nanoparticle encapsulated molecules for controlled release.
Abstract: The present invention discloses a method for synthesizing a new ferrihydrite nano-photosensitizer, comprising steps of: weighing 303 mg of Fe(NO3)3?9H2O solid dissolved fully in 30 ml of distilled water to prepare a 0.75 mM of Fe(NO3)3 solution in water; adding PEG solid to the solution in water by stirring to fully dissolve at a molar ratio of PEG to Fe3+ of 1:1-1:50; stirring the obtained solution under heating at 75° C. in a water bath for 10-50 minutes, and then immediately cooling in an ice bath after removing; centrifuging and washing the cooled mixed solution at high speed under low temperature with the supernatant discarded, to obtain pellets as PEG-modified ferrihydrite nanoparticles (PEG-Fns). The PEG-Fns synthesized in the present invention can be controllably induced and reduced by blue light to release Fe2+, and then produce ?OH through Fenton reaction of Fe2+ and H2O2 in the cell, which induces cell oxidative damage, thereby achieving controllable anticancer and antibacterial purposes.